About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

NCT03424473·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Seagen Inc.

Age

Any age

Sex

Any

Healthy volunteers

Not accepted

You may be eligible if

\-

You may not be if

\-

The record

StatusNo longer available

PhaseNo phase

Taking part—

Started—

UpdatedFeb 25, 2020

Clareo Health | Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer